Biogen (BIIB.US) stock has been halted after the FDA has approved its controversial Alzheimer drug Aducanumab using an accelerated approval pathway. It is the first Alzheimer's treatment approved in 18 years, according to CNBC. Biogen still needs to conduct a postapproval clinical trial and FDA pointed out that the approval may be withdrawn upon unfavorable results.
Biogen (BIIB.US) stock was halted for trading at $286.10 and awaits reopening. Source: xStation5
Microsoft: Hedge Fund Sharply Cuts Position and Warns About AI Risks
Cloudflare: strong results, weak outlook, and a painful market reaction
US Open: Earnings season and strong NFP report drive Wall Street higher!
CoreWeave results: Expansion without profit and without direction